Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Leveraging novel CD38 targeted antibody-drug-conjugates for the treatment of multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

YJYead JewelCity Of Hope National Medical CenterHCHyeran ChoiCity Of Hope National Medical CenterAKAmrita KrishnanCity Of Hope National Medical Center

Discussion

Loading...

Member takes

Overview

Advanced antibody-drug conjugates show improved efficacy against multiple myeloma in vitro and in vivo, suggesting new therapeutic interventions.

Key Points

  • This research aims to improve treatment outcomes for multiple myeloma patients by developing novel CD38 targeted antibody-drug conjugates (ADCs).
  • Developed unique anti-CD38 antibodies through advanced protein engineering techniques.
  • Conducted extensive biophysical analysis using methods like surface plasmon resonance and X-ray crystallography.
  • Evaluated in vitro efficacy of ADCs against MM cell lines and assessed in vivo efficacy in NSG mice engrafted with MM cells.
  • Engineered an anti-CD38 ADC with optimized affinity and distinct binding epitope compared to daratumumab.
  • Demonstrated superior in vitro killing activity of the new ADC compared to daratumumab.
  • Preliminary in vivo data showed potent anti-tumor responses in mice treated with the new ADC compared to controls.

Cite This Study

Jewel et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db81https://doi.org/10.1182/blood-2025-2161
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 1890: HMA800067, a novel CD38-targeting antibody-drug conjugate (ADC), demonstrated superior anti-tumor activity to daratumumab in preclinical B-cell malignancies models2024
  2. 2Biparatopic targeting of CD38 using CD38-specific trimeric antibody recruiters improves cytotoxicity against multiple myeloma2026
  3. 3Modulating CD38 enzymatic activity during antibody-based immunotherapy in multiple myeloma: a basic science perspective2026 · 4 citations
  4. 4Preclinical characterization of a novel investigational monoclonal antibody CM313 with potent CD38-positive cell killing activity2024 · 9 citations
  5. 5Lbl-076, a first-in-class GPRC5DxCD38xCD3 trispecific T cell engager (TCE) for the treatment of relapsed/refractory multiple myeloma2025